#AutoHCT - Twitter Hashtag

almost 2 years ago

@MostafaFaisal14 📊 EBMT Study: Auto-HCT in THRLBCL 2-year PFS: 78% (vs 59% in DLBCL). 2-year OS: 81% (vs 74%). Relapse incidence: 16% (vs 35%). Auto-HCT is highly effective for salvage-sensitive THRLBCL. Consolidation of chemosensitive disease recommended! #Oncology #AutoHCT #THRLBCL

0

4

0

1

114

Meghan Skiba, PhD, MS, MPH, RDN @doctor_skiba

over 2 years ago

We found mobility declined early post #autoHCT and rebounded for some, but not all in #hemonc in an analysis with @winters_stone https://t.co/GaxQH3wFff

0

2

1

0

52

Mehdi Hamadani, MD @MediHumdani

over 2 years ago

Dr. Othman Akhtar @MCWCancerCenter Clarifying best #autoHCT conditioning for older #PCNSL patients #lymsm #bmtsm #EBMT24 @TheEBMT

MediHumdani's tweet photo. Dr. Othman Akhtar @MCWCancerCenter Clarifying best #autoHCT conditioning for older #PCNSL patients #lymsm #bmtsm #EBMT24 @TheEBMT https://t.co/PpBejIJOaG

1

50

17

11

4K

Transplantation and Cellular Therapy Journal @ASTCT_Journal

over 2 years ago

After retrospectively reviewing medical records of patients with multiple myeloma who underwent #autohct & later developed therapy-related myelodysplastic syndrome & #AML, the authors found that 62% had TP53 gene mutations. Read all the characteristics: https://t.co/HKixJ6T3Qt

ASTCT_Journal's tweet photo. After retrospectively reviewing medical records of patients with multiple myeloma who underwent #autohct & later developed therapy-related myelodysplastic syndrome & #AML, the authors found that 62% had TP53 gene mutations. Read all the characteristics: https://t.co/HKixJ6T3Qt https://t.co/Dr7bvBBwPq

0

11

2

1

1K

Transplantation and Cellular Therapy Journal @ASTCT_Journal

almost 3 years ago

Researchers evaluated the outcomes of newly diagnosed MM patients with ultra-high-risk MM who underwent #autoHCT and found the median progression-free survival was 22.9 months & the median overall survival was 71.5 months. Read the full article: https://t.co/eTB2zG49Yn #MMMsm

ASTCT_Journal's tweet photo. Researchers evaluated the outcomes of newly diagnosed MM patients with ultra-high-risk MM who underwent #autoHCT and found the median progression-free survival was 22.9 months & the median overall survival was 71.5 months. Read the full article: https://t.co/eTB2zG49Yn #MMMsm https://t.co/BsVbrQQKq3

0

7

4

2K

ASTCT

@ASTCT

almost 3 years ago

Live from #RelapseConference23! Today's schedule of sessions features topics on immune reconstitution, microbiome, mechanisms of relapse after #alloHCT or #autoHCT, #CARTcells resistance and more. https://t.co/r5oYIW87n2

ASTCT's tweet photo. Live from #RelapseConference23! Today's schedule of sessions features topics on immune reconstitution, microbiome, mechanisms of relapse after #alloHCT or #autoHCT, #CARTcells resistance and more. https://t.co/r5oYIW87n2 https://t.co/GHf6xDYPb8

0

5

1

0

1K

Jose Sandoval S, MD FACP 🇨🇴🇨🇴 @HemSandoval

over 3 years ago

@GomezDLeonMD Then again, is there a another good option in these high population, especially for the folks with primary refractory disease?. A tiny small group can be salvage with #AutoHCT but overall…muy malo….

0

2

0

157

JCO Oncology Practice @JCOOP_ASCO

over 4 years ago

Patients w/ #lymphoma in remission at 3 & 6 years after diagnosis had a durable, high level of #QOL w/ no significant differences associated w/ history of #autoHCT. At 3 yrs, anxiety is a little ↓ in the autoHCT group. #JCOOP @strouse_chris https://t.co/6cyOJetNTJ #lymsm

JCOOP_ASCO's tweet photo. Patients w/ #lymphoma in remission at 3 & 6 years after diagnosis had a durable, high level of #QOL w/ no significant differences associated w/ history of #autoHCT. At 3 yrs, anxiety is a little ↓ in the autoHCT group. #JCOOP @strouse_chris https://t.co/6cyOJetNTJ #lymsm https://t.co/cWL6vHWFIU

0

4

3

0

Haematologica @Haematologica

over 4 years ago

The retrospective data presented by Mei et al. suggest that #autoHCT still has a role in R/R chemosensitive #DLBCL even in later lines of therapy. For those patients, #CAR-T can be held in reserve in case of relapse after transplant. https://t.co/npokpc3kFx

Haematologica's tweet photo. The retrospective data presented by Mei et al. suggest that #autoHCT still has a role in R/R chemosensitive #DLBCL even in later lines of therapy. For those patients, #CAR-T can be held in reserve in case of relapse after transplant.
https://t.co/npokpc3kFx https://t.co/fWuBxU13kU

0

10

5

2

0

Hemalatha Rangarajan MD https @hmgcoa2

over 4 years ago

@RahulBanerjeeMD @szusmani This is funny! now as a pedsbmt doc I am.totally get #MMsm #autohct rules 😀 never going to forget this piece of info.

0

2

0

NMDP @nmdp_org

over 4 years ago

Early referral for #HCT consultation is critical for optimal transplant outcomes if #alloHCT or #autoHCT is indicated for your patient. For many patients, there may be a narrow window to proceed to transplant. See the HCT consultation guidelines: https://t.co/HZBuLWWxOM

nmdp_org's tweet photo. Early referral for #HCT consultation is critical for optimal transplant outcomes if #alloHCT or #autoHCT is indicated for your patient. For many patients, there may be a narrow window to proceed to transplant.

See the HCT consultation guidelines: https://t.co/HZBuLWWxOM https://t.co/cY4ZgpLOBO

0

11

6

0

UChicago Medicine Comprehensive Cancer Center @UCCancerCenter

almost 5 years ago

#MantleCellLymphoma is a rare form of B-cell #nonHodgkinslymphoma. @SoniSmithMD and colleagues analyzed overall survival of patients receiving autologous hematopoietic cell transplantation #autoHCT over the course of 19 years in this @ASTCT_Journal paper: https://t.co/I99QKu0jIY

0

3

0

Alexander Link

@alinkmd

over 5 years ago

Microbioal diversity predicts outcome in recipients of autologous hematopoietic cell transplantation (#autoHCT) -a multicenter observational study -n=1161 -Loss of diversity and domination by specific bacterial taxa occurred are common https://t.co/ULlU7oDLbm

alinkmd's tweet photo. Microbioal diversity predicts outcome in recipients of autologous hematopoietic cell transplantation (#autoHCT)

-a multicenter observational study
-n=1161
-Loss of diversity and domination by specific bacterial taxa occurred are common

https://t.co/ULlU7oDLbm https://t.co/Vb9EMC2Gre

0

2

0

Mehdi Hamadani, MD @MediHumdani

almost 6 years ago

Long term IFM2009 follow up in #myeloma. Early vs. Late #autoHCT Median PFS 47 vs. 35 months in favor of early autoHCT 35% of patients in HCT group still 2nd line free after 8 years OS similar #bmtsm

MediHumdani's tweet photo. Long term IFM2009 follow up in #myeloma. Early vs. Late #autoHCT
Median PFS 47 vs. 35 months in favor of early autoHCT
35% of patients in HCT group still 2nd line free after 8 years
OS similar #bmtsm https://t.co/6lJhjLfdDw

2

15

5

4

0

Mehdi Hamadani, MD @MediHumdani

almost 6 years ago

Forte Trial: Followup #ASH20 Response, including MRD favored #autoHCT. 3-year PFS suprior with HDT. #mmsm #bmtsm

0

10

2

0

Hematologia ICO Hospitalet @HematICO_Hosp

over 7 years ago · Barcelona

📚🔍🔬Great presentation by Dr Paula Rodríguez from @unav at our Educational Session @ICOnoticies...state of the art about #MultipleMyeloma #Daratumumab #solitaryplasmocytoma #autoHCT Check out some highlights👇👇👇

HematICO_Hosp's tweet photo. 📚🔍🔬Great presentation by Dr Paula Rodríguez from @unav at our Educational Session @ICOnoticies...state of the art about #MultipleMyeloma #Daratumumab #solitaryplasmocytoma #autoHCT
Check out some highlights👇👇👇 https://t.co/Uyxzsg01or

0

10

1

0

Susan Keown @sejkeown

about 8 years ago

This story was fascinating to come across— mouse model research on #myeloma immunology that has challenged decades of conventional wisdom & is opening hopeful new avenues for tx. TL;DR: #autoHCT = #immunotherapy https://t.co/8JJaLdxy2v

1

5

2

0

Stephanie Farnia @SFarnia_

over 8 years ago

Great new reference article from @GunjanLShah evaluating cost-effectiveness of #AutoHCT against @icer_review thresholds. https://t.co/8ICr2hKQDK

0

5

1

0

Top Tweets for #AutoHCT

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users